LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancer
Our findings that BRAF plus EGFR inhibition induces lineage plasticity in BRAF<sup>V600E</sup> CRC represents a new paradigm for how resistance to BRAF plus EGFR inhibition occurs. Additionally, our finding that LSD1 inhibition blocks lineage plasticity has the potential to improve responses to BRAF plus EGFR inhibitor therapy in patients.
Authors
- Ashiq Masood (ORCID: https://orcid.org/0000-0002-1848-1178)
- Averi Chakraborty (ORCID: https://orcid.org/0000-0002-4379-4782)
- Heather M. O’Hagan (ORCID: https://orcid.org/0000-0001-9750-5088)
- Galen Hostetter (ORCID: https://orcid.org/0000-0003-2616-6861)
- Joo Mi Yi
- Christopher A. Ladaika (ORCID: https://orcid.org/0009-0009-3356-1924)
Institutions
- Inje University (KR)
- Indiana University Health (US)
- Van Andel Institute (US)
- Indiana University Bloomington (US)
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Molecular Cancer
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1186/s12943-025-02311-z
- Citations
- 4
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- National Institutes of Health
- Indiana University Bloomington
- School of Medicine, Indiana University
- National Cancer Institute